Welcome to our dedicated page for Io Biotech SEC filings (Ticker: IOBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, cash runway projections, and dilution risk make IO Biotech’s SEC filings some of the densest documents in immuno-oncology. If you have ever searched a 300-page 10-K for one line on IDO or PD-L1 progress, you know the challenge.
Stock Titan decodes those disclosures in seconds. Our AI-powered summaries turn every IO Biotech annual report 10-K simplified, each IO Biotech quarterly earnings report 10-Q filing, and every IO Biotech 8-K material events explained into plain language. You also get real-time alerts the moment an IO Biotech Form 4 insider transactions real-time notice hits EDGAR—so monitoring executive stock transactions or sudden financing announcements never requires manual refreshes.
Wonder what to track? Our platform links filing types to IO Biotech’s unique story:
- 10-K: R&D burn rate, clinical pipeline timelines, risk factors—IO Biotech SEC filings explained simply
- 10-Q: quarter-over-quarter cash usage—perfect for an IO Biotech earnings report filing analysis
- 8-K: fast updates on trial milestones or equity offerings—IO Biotech 8-K material events explained
- Form 4: IO Biotech insider trading Form 4 transactions and IO Biotech executive stock transactions Form 4
- DEF 14A: IO Biotech proxy statement executive compensation without sifting through legal jargon
Whether you’re comparing pipeline progress, assessing dilution risk, or timing entry around insider activity, Stock Titan delivers the complete picture—updated the instant IO Biotech files.
IO Biotech (Nasdaq: IOBT) filed an 8-K announcing that it has met the conditions to draw the €12.5 million Tranche B of its previously disclosed €57.5 million term-loan facility with the European Investment Bank (EIB).
In exchange, the EIB received a warrant to purchase up to 4,221,867 shares of common stock at a strike price of $1.3159. The drawdown is expected on or about July 4, 2025.
- The warrant and the underlying shares were issued in a private placement relying on Section 4(a)(2).
- Key warrant terms are unchanged from the December 20 2024 filing.
The transaction bolsters near-term liquidity but introduces potential dilution for existing shareholders.
IO Biotech, Inc. (Nasdaq: IOBT) filed a Form 8-K to disclose an Addendum to the 2017 service agreement with Chief Executive Officer Mai-Britt Zocca, Ph.D. The addendum, executed 19 June 2025 by subsidiary IO Biotech ApS, formalises severance and change-in-control protections.
Standard Qualifying Termination (without cause or by the CEO for good reason) entitles the CEO to:
- Cash severance equal to 12 months of current base salary.
- Pro-rated annual bonus for the year of termination, calculated on actual performance.
- Any unpaid prior-year bonus.
- Accelerated vesting of equity awards scheduled to vest within 12 months after termination, with performance awards vesting on actual results.
Change-in-Control (CIC) Protection: If a Qualifying Termination occurs within six months before or 12 months after a CIC, (i) cash severance increases to 18 months of base salary, (ii) the current-year bonus is paid at full, non-prorated value, and (iii) 100 % of outstanding equity vests immediately, with performance goals deemed met at target or as otherwise specified in award agreements.
All payments are contingent on execution and non-revocation of a general release of claims. The company attached the Addendum as Exhibit 10.1; no other financial statements or exhibits were included.
The disclosure does not alter current operations or financial guidance but increases potential cash outflows and equity dilution in a termination or CIC scenario. Investors should note the enhanced protection may aid retention during strategic discussions but could represent a modest cost if triggered.
FAQ
What is the current stock price of Io Biotech (IOBT)?
What is the market cap of Io Biotech (IOBT)?
What is the primary focus of IO Biotech Inc.?
How does IO Biotech generate value for the market?
What differentiates IO Biotech from other biopharmaceutical companies?
What role does T-win technology play in IO Biotech's strategy?
What types of therapeutic targets does the company focus on?
How advanced is IO Biotech's clinical pipeline?
What is the significance of the management team at IO Biotech?
How should investors view the developmental stage of IO Biotech's therapies?
